[Skip to Navigation]
Invited Commentary
July 18, 2019

Molecular Testing for Indeterminate Thyroid Nodules—When the Rubber Meets the Road

Author Affiliations
  • 1Department of Surgery, Endocrine & Breast Surgery, Weill Cornell Medical Center, New York, New York
  • 2Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Otolaryngol Head Neck Surg. 2019;145(9):792-793. doi:10.1001/jamaoto.2019.1465

In this issue of JAMA Otolaryngology Head & Neck Surgery, Valderrabano et al1 report provocative findings on the performance of a widely used molecular test for thyroid nodules. The authors’ goal was to determine whether the performance of this assay, the Afirma gene expression classifier (GEC; Veracyte), in the real world has matched the figures in the initial validation study that led to the approval and widespread adoption of the GEC. Undertaking a systematic review of 19 studies encompassing 2568 nodules, the authors found that the sensitivity and specificity of the test seemed to differ markedly from those reported in the initial study.2

Add or change institution